November 24th and 25th
Royal Palm Hall - Campinas/SP
LOT 1 Released
Latin America's Leading Congress on Endocannabinoid Medicine
The Future of Medicine unveiled in 2 days of connection, knowledge and market innovations.
What the WeCann Summit? is all about?
The WeCann Summit is the main congress exclusively for physicians on Endocannabinoid Medicine in Latin America.
If you are a physycian who works or wants to work with Endocannabinoid Medicine, this event is for you
Held by the WeCann Academy, an international reference in the training and education of physicians in the field, the WeCann Summit comes with plenitude of highly qualified technical content, unprecedented in Brazil, on the main scientific advances in the field.
Knowledge, quality networking and lots of innovative ideas and solutions are awaiting you at the WeCann Summit 2023!
2 DAYS OF IMMERSION IN 30+ LECTURES
EXPO FAIR WITH THE MAIN SOLUTIONS ON THE MARKET
Check out testimonials from fellow doctors who have taken part in WeCann Academy events
- Dr. Eduardo K.
- MD| General Practitioner
- "It was a learning journey for all levels of knowledge, with excellent teaching and great teachers!"
- Dra. Rafaela D.
- MD | Pain Physician and Anesthesiologist
- "I hope to use this knowledge to relieve my patients’ pain! Today I feel prepared to serve them safely, thanks to WeCann! Thank you!"
- Dr. Guilherme B.
- MD | Sports Medicine Physician
- "It changed my life and my perception of medicine and care as a whole."
- Dra. Fernanda C.
- MD | Psychiatrist
- "It broadened my horizon on new ways of clinical application, humanized and particularized follow-up, worldwide experience of the ecosystem! Thank you for every second of knowledge!"
- Dra. Tânia Cristina P.
- MD | Pediatrician and Homeopathic pyhsicia
- "Great experts who share rich content clearly and generously!"
- Dra. Ana Claudia B.
- MD| Neurophysiologist
- "The case discussions undoubtedly consolidate daily practice. Everything was excellent!"
Confirmed Speakers
Franjo Grotenhermen
Franjo Grotenhermen
MD, researcher, and author, Franjo Grotenhermen is an international reference in Endocannabinoid Medicine. For over 20 years, Franjo has been studying the therapeutic potential of the Cannabis plant. He is the author of a series of articles, books, and book chapters on the clinical applications, pharmacology, and toxicology of cannabinoid derivatives, being one of the pioneering doctors in systematizing this knowledge worldwide. He is the founder of the International Alliance for Cannabinoid Medicines (IACM), the oldest and most relevant medical society in the world that promotes scientific understanding of Endocannabinoid Medicine.
His biography was portrayed in the documentary “The Doctor,” widely acclaimed at film festivals around the world. Below is a selection of his main publications in the field:
Main Publications
Grotenhermen, F. (2003). Pharmacokinetics and pharmacodynamics of cannabinoids. Clinical pharmacokinetics, 42, 327-360.
Grotenhermen, F., & Russo, E. (2002). Cannabis and cannabinoids: pharmacology, toxicology, and therapeutic potential. Psychology Press.
Grotenhermen, F. (2004). Cannabinoids for therapeutic use: designing systems to increase efficacy and reliability American Journal of Drug Delivery, 2, 229-240.
Grotenhermen, F. (2007). The toxicology of cannabis and cannabis prohibition. Chemistry & biodiversity, 4(8), 1744-1769.
Grotenhermen, F., & Müller-Vahl, K. (2016). Medicinal uses of marijuana and cannabinoids. Critical Reviews in Plant Sciences, 35(5-6), 378-405.
Patricia Montagner
Patricia Montagner
MD, neurosurgeon certified by the World Institute of Pain (WIP) for minimally invasive procedures in pain (Fellow of Interventional Pain Practice).
Technical director of NeuroVinci Clinic, where she oversees more than 2,000 patients applying Endocannabinoid Medicine.
Founder of WeCann Academy, a Global Community for studies in Endocannabinoid Medicine, which already has more than 1,800 physicians from various countries.
Creator and host of WeCann Summit.
Ethan Russo
Ethan Russo
MD, neurologist, psychopharmacologist, researcher, and author, Ethan Russo is an unparalleled figure in scientific research on medical cannabis. For over 20 years, Ethan has dedicated his studies to exploring the therapeutic potential of the cannabis plant. He has authored numerous articles, books, and book chapters in the field, establishing himself as one of the pioneering physicians to systematize this knowledge worldwide. With over 50 scientific articles published in the field, he has made significant contributions to the education of Endocannabinoid Medicine in more than 30 countries.
From 2003 to 2014, Ethan served as the Medical Senior Advisor for the British pharmaceutical company GW. During this time, he actively participated in several phase I-III clinical studies of Sativex® Sativex® is a THC and CBD-based formulation registered in dozens of countries for its effectiveness in relieving pain associated with spasticity in multiple sclerosis. Additionally, Ethan played a vital role in the initial studies of Epidiolex®, a CBD-based drug registered by the FDA for the treatment of refractory epilepsies. Currently, Ethan serves as the founder and CEO of CReDO Science.
Below, you will find a selection of his key publications in the field:
Main Publications
Russo, E. (2001). Cannabis therapeutics in HIV/Aids. Psychology Press.
Russo, E. (2002). The Last Sorcerer: Echoes of the Rainforest. Psychology Press.
Russo, E., Dreher, M. C., & Mathre, M. L. (2002). Women and cannabis: Medicine, science, and sociology. Psychology Press.
Russo, E. (2003). Cannabis: from pariah to prescription. Psychology Press.
Grotenhermen, F., & Russo, E. B. (2006). Handbook of Cannabis Therapeutics: From Bench to Bedside;[a Compilation of Selected Articles from the Journal of Cannabis Therapeutics… from 2001 to 2004]. Haworth Press.
Russo, E. B. (2013). Cannabis and cannabinoids: pharmacology, toxicology, and therapeutic potential. Routledge.
Russo, E. B., & Tyler, V. M. (2015). Handbook of psychotropic herbs: A scientific analysis of herbal remedies for psychiatric conditions.
Russo, E. B. (2019). The case for the entourage effect and conventional breeding of clinical cannabis: no “strain,” no gain. Frontiers in plant science, 9, 1969.
Russo, E. B., Plumb, J., & Whiteley, V. L. (2021). Novel solventless extraction technique to preserve cannabinoid and terpenoid profiles of fresh cannabis inflorescence. Molecules, 26(18), 5496.
Adán de Salas Quiroga
Adán de Salas Quiroga
Adán de Salas Quiroga is a biologist and specialist in Neurobiology. He obtained a Master’s degree in Biochemistry, Molecular Biology, and Biomedicine from the Complutense University of Madrid. In 2017, he received his Ph.D. from the same university, with a study on the role of the Endocannabinoid System during the development of the mammalian embryonic brain and the impact of prenatal exposure to this therapy. Adán has worked as a postdoctoral researcher in renowned national and international institutions, where he received additional training in electrophysiology and cancer.
Currently, he is dedicated to providing high-quality education to healthcare professionals and companies about cannabis and the endocannabinoid system.
Below is a selection of his main publications in the field:
Main Publications
de Salas-Quiroga, A., Díaz-Alonso, J., García-Rincón, D., Remmers, F., Vega, D., Gómez-Cañas, M., … & Galve-Roperh, I. (2015). Prenatal exposure to cannabinoids evokes long-lasting functional alterations by targeting CB1 receptors on developing cortical neurons. Proceedings of the National Academy of Sciences, 112(44), 13693-13698.
Díaz-Alonso, J., de Salas-Quiroga, A., Paraíso-Luna, J., García-Rincón, D., Garcez, P. P., Parsons, M., … & Galve-Roperh, I. (2017). Loss of cannabinoid CB1 receptors induces cortical migration malformations and increases seizure susceptibility.
de Salas-Quiroga, A., García-Rincón, D., Gómez-Domínguez, D., Valero, M., Simón-Sánchez, S., Paraíso-Luna, J., … & Galve-Roperh, I. (2020). Long-term hippocampal interneuronopathy drives sex-dimorphic spatial memory impairment induced by prenatal THC exposure. Neuropsychopharmacology, 45(5), 877-886.
Ricardo Ferreira
Ricardo Ferreira
MD, specialized in Orthopedics and Traumatology from the Federal University of Rio de Janeiro, Ricardo Ferreira has accumulated over ten titles in his field throughout his career.
These include being a specialist in Orthopedics and Traumatology certified by the Ministry of Education (MEC), the Brazilian Society of Orthopedics and Traumatology (SBOT), and the Brazilian Medical Association (AMB). He is a full member of the Brazilian Society of Orthopedics and Traumatology and the Brazilian Society of Spine Surgery.
He is also a member of the North American Spine Society (NASS) and an expert in Spine as well as a member of AO Spine International. Additionally, he holds a specialization in pain from the Brazilian Society for the Study of Pain and an MBA in Healthcare Management from COPPEAD.
Ricardo Ferreira is one of the pioneering doctors in the application of Endocannabinoid Medicine in Brazil.
Javier Diaz Alonso
Javier Diaz Alonso
Javier Diaz Alonso is a biochemist with a Master’s and PhD in Biochemistry and Molecular Biology from the Universidad Complutense de Madrid. He currently holds the position of Assistant Professor in the Department of Anatomy and Neurobiology at UC Irvine School of Medicine in the USA. Javier is recognized for his contributions in basic science research, particularly in the areas of the endocannabinoid and glutamatergic systems.
Below, you will find a selection of his significant publications in the field:
Main Publications:
Díaz-Alonso, J., de Salas-Quiroga, A., Paraíso-Luna, J., García-Rincón, D., Garcez, P. P., Parsons, M., … & Galve-Roperh, I. (2017). Loss of cannabinoid CB1 receptors induces cortical migration malformations and increases seizure susceptibility. Cerebral Cortex, 27(11), 5303-5317.
Díaz-Alonso, J., Sun, Y. J., Granger, A. J., Levy, J. M., Blankenship, S. M., & Nicoll, R. A. (2017). Subunit-specific role for the amino-terminal domain of AMPA receptors in synaptic targeting. Proceedings of the National Academy of Sciences, 114(27), 7136-7141.
Díaz-Alonso, J., Morishita, W., Incontro, S., Simms, J., Holtzman, J., Gill, M., … & Nicoll, R. A. (2020). Long-term potentiation is independent of the C-tail of the GluA1 AMPA receptor subunit. Elife, 9, e58042.
Tina Horsted
Tina Horsted
Tina Horsted has over 30 years of experience in treating patients. She has received training and certification from SSAI (Scandinavian Society of Anaesthesiology and Intensive Care Medicine) in pain management. In 2018, she published the book “Medical Cannabis – Quality of Life and Pain Relief with Cannabis Medicine.”
Recently, as a founder of the Horsted Institute, Tina compiled data from 2016-2018 on over 2,400 chronic pain patients treated with medical cannabis. Below are some of her key publications in the field:
Main Publications
Hendricks, O., Andersen, T. E., Christiansen, A. A., Primdahl, J., Hauge, E. M., Ellingsen, T., … & Petersen, K. H. (2019). Efficacy and safety of cannabidiol followed by an open label add-on of tetrahydrocannabinol for the treatment of chronic pain in patients with rheumatoid arthritis or ankylosing spondylitis: protocol for a multicentre, randomised, placebo-controlled study. BMJ open, 9(6), e028197.
Bhaskar, A., Bell, A., Boivin, M., Briques, W., Brown, M., Clarke, H., … & Moulin, D. E. (2021). Consensus recommendations on dosing and administration of medical cannabis to treat chronic pain: results of a modified Delphi process. Journal of cannabis research, 3, 1-12.
Horsted, T., Hesthaven, K. L., & Leutscher, P. D. C. (2023). Safety and effectiveness of cannabinoids to Danish patients with treatment refractory chronic pain—A retrospective observational real‐world study. European Journal of Pain, 27(2), 234-247.
Mara Gordon
Mara Gordon
Mara Gordon is a globally recognized leader in the field of Endocannabinoid Medicine.
With her background as a Process Engineer assisting Fortune 500 companies in creating intelligent software, she has applied her expertise to develop cannabis formulations and therapeutic dosing regimens for thousands of patients in California, USA.
Mara is dedicated to openly sharing her knowledge and expertise regarding the therapeutic benefits of the cannabis plant through lectures, courses, conferences, and TEDx Talks. She consistently advocates for serious and responsible positions within the cannabis industry, which she deeply cares about.
Her groundbreaking work with medical cannabis was recently featured in the documentary “Weed the People” by Ricki Lake and Abby Epstein, available on Netflix.
Kirsten Müller-Vahl
Kirsten Müller-Vahl
Kirsten Müller-Vahl is an expert in neurology and adult psychiatry, currently holding a professorship in psychiatry at the Department of Psychiatry, Hannover Medical School in Germany. With a research career spanning over twenty years, Müller-Vahl has focused on investigating the therapeutic effects of medical cannabis in the treatment of tics, particularly in more than 1500 patients with Tourette syndrome and other psychiatric disorders.
Müller-Vahl serves as the principal investigator in numerous studies, which have received funding from prestigious institutions such as the German Research Support Society, the German Federal Ministry of Education and Research, the European Union, and industry sponsors. These studies explore the efficacy of cannabis-based medicines and cannabinoid modulators. Additionally, Müller-Vahl actively contributes to the scientific community as a member of the scientific advisory board of the Tourette Society Germany and as a board member of the International Alliance for Cannabinoid Medicines (IACM).
Below, you will find a selection of her key publications in the field:
Main Publications:
Müller-Vahl, K. R., Schneider, U., Koblenz, A., Jöbges, M., Kolbe, H., Daldrup, T., & Emrich, H. M. (2002). Treatment of Tourette’s syndrome with Δ9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry, 35(02), 57-61.
Muller-Vahl, K. R., Schneider, U., Prevedel, H., Theloe, K., Kolbe, H., Daldrup, T., & Emrich, H. M. (2003). D9-Tetrahydrocannabinol (THC) is Effective in the Treatment of Tics in Tourette Syndrome: A 6-Week Randomized Trial. Journal of Clinical Psychiatry, 64(4), 459-465.
Müller-Vahl, K. R., & Emrich, H. M. (2008). Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia. Expert Review of Neurotherapeutics, 8(7), 1037-1048.
Grotenhermen, F., & Müller-Vahl, K. (2012). The therapeutic potential of cannabis and cannabinoids. Deutsches Ärzteblatt International, 109(29-30), 495.
Pringsheim, T., Okun, M. S., Müller-Vahl, K., Martino, D., Jankovic, J., Cavanna, A. E., … & Piacentini, J. (2019). Practice guideline recommendations summary: treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology, 92(19), 896-906.
Kirsten R Müller-Vahl and others, Stop that! It’s not Tourette’s but a new type of mass sociogenic illness. Neurology, 92(19), 896-906.
Daniele Piomelli
Daniele Piomelli
Neuroscientist, author of more than 420 peer-reviewed articles, three full-length books and more than 35 patents. Since 2018, Daniele is Editor-in-Chief of the specialised journal “Cannabis and Cannabinoid Research”.
Daniele Piomelli is Professor Emeritus of Anatomy and Neurobiology at the University of California, Irvine.
Below are some of his major publications in the field:
Main Publications:
Piomelli, D., Volterra, A., Dale, N., Siegelbaum, S. A., Kandel, E. R., Schwartz, J. H., & Belardetti, F. (1987). Lipoxygenase metabolites of arachidonic acid as second messengers for presynaptic inhibition of Aplysia sensory cells. Nature, 328(6125), 38-43.
Piomelli, D., Giuffrida, A., Calignano, A., & de Fonseca, F. R. (2000). The endocannabinoid system as a target for therapeutic drugs. Trends in pharmacological sciences, 21(6), 218-224.
Piomelli, D. (2003). The molecular logic of endocannabinoid signalling. Nature Reviews Neuroscience, 4(11), 873-884.
Ruiz, C. M., Torrens, A., Lallai, V., Castillo, E., Manca, L., Martinez, M. X., … & Mahler, S. V. (2021). Pharmacokinetic and pharmacodynamic properties of aerosolized (“vaped”) THC in adolescent male and female rats. Psychopharmacology, 238, 3595-3605.
Piomelli, D., & Mabou Tagne, A. (2022). Endocannabinoid-based therapies. Annual Review of Pharmacology and Toxicology, 62, 483-507.
Fotio, Y., Mabou Tagne, A., Jung, K. M., & Piomelli, D. (2023). Fatty acid amide hydrolase inhibition alleviates anxiety-like symptoms in a rat model used to study post-traumatic stress disorder. Psychopharmacology, 1-11.
Paola Pineda
Paola Pineda
MD specializing in medical law from the Universidad Pontificia Bolivariana and a Master’s in HIV from the Universidad Rey Juan Carlos.
Paola has been utilizing cannabis as a therapeutic tool for eight years and has assisted over 5,000 patients.
Paola Pineda is a founding member of the Curativa group in Colombia, where she focuses on researching the therapeutic potential of the cannabis plant and possible synergies with other substances.
Eduardo Faveret
Eduardo Faveret
Eduardo Faveret completed his graduate studies in Pediatric Neurology at the Federal University of Rio de Janeiro and specialized in Clinical Neurophysiology and Epileptology at Bonn Universität and Bethel Epilepsie Zentrum in Germany.
He was the founder and medical director of the Epilepsy Centers at the Paulo Niemeyer State Brain Institute and CEPIRIO RIO.
In 2013, he became one of the first Brazilian doctors to prescribe medical cannabis and has since treated over 4,000 patients with various neurological diseases throughout the country.
Mery Peña
Mery Peña
Mery Peña is a Colombian MD who graduated in Medicine from the National University of Colombia. She has been practicing in Barcelona for 10 years, focusing on mental health.
Prior to joining the medical team at Kalapa Clinic, Europe’s first medical consultancy specializing in Endocannabinoid Medicine, Mery Peña worked in palliative care and geriatrics. At Kalapa Clinic, she specialized in assisting patients through the use of medical cannabis.
Mery is a member of the Society of Cannabis Clinicians (SCC) and currently serves as the secretary of the Clinical Society of Endocannabinology of Spain.
Diego Cruz
Diego Cruz
MD, surgeon graduated from the University of Santiago de Chile, with a Master’s degree in Mountain Medicine from the University of Insubria, Italy.
For the past 6 years, he has been providing medical care at the Daya Foundation, one of the most relevant associations for medical cannabis patients in Latin America. He is a scholar on the use of phytocannabinoids in palliative care, chronic pain, and Autism Spectrum Disorder.
Diego has extensive experience in national and international conferences and university courses related to the medical use of cannabis.
Adi Aran
Adi Aran
Dr. Adi Aran is a renowned pediatric neurologist and the director of the Neuropediatrics unit at Shaare Zedek Medical Center in Jerusalem. His research focuses on the involvement of the endocannabinoid system in Autism Spectrum Disorder (ASD) and related genetic disorders, as well as the evaluation of novel therapeutics for these conditions. Dr. Aran is a board member of the Israeli Society of Pediatric Neurology and a member of the International Society for Autism Research.
In 2017, Dr. Aran initiated an innovative project aimed at evaluating 120 children with Autism Spectrum Disorder (ASD). This groundbreaking study, funded by the Israeli government, was the first of its kind in the world. The project was motivated by the increasing interest in the potential therapeutic applications of cannabis for ASD.
Below are some of his major publications in the field:
Main Publications:
Aran, A., Cassuto, H., Lubotzky, A., Wattad, N., & Hazan, E. (2019). Brief report: cannabidiol-rich cannabis in children with autism spectrum disorder and severe behavioral problems—a retrospective feasibility study. Journal of Autism and Developmental Disorders, 49(3), 1284-1288.
Aran, A., Eylon, M., Harel, M., Polianski, L., Nemirovski, A., Tepper, S., … & Tam, J. (2019). Lower circulating endocannabinoid levels in children with autism spectrum disorder. Molecular autism, 10(1), 1-11.
Aran, A., & Cayam-Rand, D. (2020). Medical cannabis in children. Rambam Maimonides Medical Journal, 11(1).
Aran, A., Harel, M., Cassuto, H., Polyansky, L., Schnapp, A., Wattad, N., … & Castellanos, F. X. (2021). Cannabinoid treatment for autism: a proof-of-concept randomized trial. Molecular autism, 12(1), 1-11.
Alberto Ulloa
Alberto Ulloa
MD, psychiatrist, graduated from the Universidad Javeriana de Bogotá, Colombia.
He is a professor in the graduate course in addiction at Luis Amigo University in Medellín. Alberto has worked with the Mental Health group in the Ministry of Health in Colombia. He practices as a psychiatrist at IPS Centro Cita de Salud Mental and also has a private practice at the Medellin del Poblado clinic.
Alberto began his studies on cannabis for therapeutic purposes in 2019 and currently provides support to patients with various psychiatric disorders using this therapeutic tool.
Mariano Garcia
Mariano Garcia
MD, surgeon, graduated from the University of Barcelona in 1979. He worked for 38 years as an emergency physician and occupational physician. For the past 17 years, he has been studying and working in the field of Endocannabinoid Medicine.
He is the founder of Kalapa Clinic in Barcelona, Spain, the first medical consultancy in Europe specialized in Endocannabinoid Medicine.
Additionally, Mariano is an active member of the Spanish Observatory of MedicalCannabis and a founding member of the Clinical Society of Endocannabinology in Spain.
Wilson Lessa
Wilson Lessa
MD, psychiatrist, graduated in Medicine from the Federal University of Mato Grosso do Sul.
He specialised in Forensic Psychiatry at the Brazilian Medical Association. Wilson is a professor of Medicine at the Federal University of Roraima and the Federal University of Paraíba, as well as a member of the International Cannabinoid Research Society (ICRS) and the Society of Cannabis Clinicians (SCC).
Harry Mcilroy
Harry Mcilroy
Harry is an MD who graduated from the Institute of Functional Medicine in the USA. He has a strong background in US Functional Medicine and has received extensive training in Osteopathy, yoga, and meditation. With over 20 years of experience, his training in Traditional Chinese Herbal Medicine introduced him to cannabinoid therapeutics.
Using his knowledge of Functional Medicine and his expertise in medical plants, Harry guides his patients on the most effective ways to stimulate each individual’s self-healing capacity.
Uwe Blesching
Uwe Blesching
Uwe Blesching is a researcher and author of several books in the field of Endocannabinoid Medicine. His notable works include “The Cannabis Health Index” (now in its 3rd edition), “Breaking the Cycle of Opioid Addiction”, e “Your Cannabis CBD:THC Ratio”.
Additionally, Uwe is a Co-founder and Scientific Director of CannaKeys360°, the world’s first online platform that gathers, organizes, and reviews thousands of scientific articles in the field of Endocannabinoid Medicine.
Leandro Ramires
Leandro Ramires
MD, oncological surgeon, and mastologist. He holds a Master’s degree in Women’s Health and Breast Cancer from the Faculty of Medicine at UFMG. He is a former coordinator and currently serves as a Preceptor Physician for the Medical Residency Program in the Mastology Department at the Hospital das Clínicas of UFMG.
Since April 2014, he has been prescribing cannabis for medicalpurposes. He has extensive experience in providing adjunctive treatment to patients with epilepsy, autism, chronic pain, Alzheimer’s, Parkinson’s, autoimmune diseases, cancer, and in palliative care. He is also a medicinal cannabis cultivator with a Safe Conduct for his son Benicio, who has Dravet Syndrome and severe Autism.
Currently, he holds the position of Scientific Medical Director at the Brazilian Medical Cannabis Patients Association (AMA+ME) and is involved in clinical research.
Guillermo Moreno Sanz
Guillermo Moreno Sanz
Guillermo Moreno Sanz is a neuroscientist with a PhD in Neurosciences. He has authored over 30 scientific articles and holds three patents that describe the role of the endocannabinoid system in pain control. Throughout his professional career, he has made significant contributions to the field of cannabinoid analgesics, conducting important research at the University of California, Irvine.
In 2017, Guillermo founded Abagune Research, a cannabis consulting company based in Spain. He has also served as a consultant for the US National Academies of Sciences, contributing to the report titledo “The Health Effects of Cannabis and Cannabinoids” . In 2020, he assumed the position of chief scientific and medical officer at Khiron Life Sciences Corp., further expanding his work in medical cannabis research and its applications.
Below are some of his major publications in the field:
Main Publications:
Moreno-Sanz, G., Barrera, B., Armirotti, A., Bertozzi, S. M., Scarpelli, R., Bandiera, T., … & Piomelli, D. (2014). Structural determinants of peripheral O-arylcarbamate FAAH inhibitors render them dual substrates for Abcb1 and Abcg2 and restrict their access to the brain. Pharmacological Research, 87, 87-93.
Sultan, W., Mathew, A., Brown, M. R., Gálvez-Flórez, J. F., & Moreno-Sanz, G. (2022). Cannabis-Based Medicinal Products in the Management of Emotionally Unstable Personality Disorder (EUPD): A Narrative Review and Case Series. Brain Sciences, 12(11), 1467.
Moreno-Sanz, G., Madiedo, A., Lynskey, M., & Brown, M. R. (2022). “Flower Power”: Controlled Inhalation of THC-Predominant Cannabis Flos Improves Health-Related Quality of Life and Symptoms of Chronic Pain and Anxiety in Eligible UK Patients. Biomedicines, 10(10), 2576.
Moreno-Sanz, G., Madiedo, A., Hernandez, P., Kratz, J., Aizpurua-Olaizola, O., Brown, M. R., … & Mendivelso, F. O. (2022). Sex-dependent prescription patterns and clinical outcomes associated with the use of two oral cannabis formulations in the multimodal management of chronic pain patients in Colombia. Frontiers in Pain Research, 3, 854795.
Ricardo Ghelman
Ricardo Ghelman
Ricardo Ghelman is a pediatrician and pediatric oncologist. He holds a Master’s degree in Comparative Anatomy and a Ph.D. in Medicine in the field of Experimental Obstetrics.
Since 2012, Ricardo has been serving as the coordinator of the Anthroposophy and Health Outpatient Clinic at the Neuromuscular Diseases Research Sector of the Federal University of São Paulo / Paulista School of Medicine.
He is also an assistant professor and guest lecturer in various graduate and specialization courses in Anthroposophic Medicine and Integrative Practices. Currently, he serves as the pedagogical coordinator of the extension course in Anthroposophic Semiology at UNIFESP.
Leslie Apgar
Leslie Apgar
Leslie Apgar is MD, gynecologist and obstetrician who specializes in minimally invasive surgery. In 2008, she founded a medical spa called Pura Vida. Since 2017, she has been serving as the Medical Director and Co-Founder of Greenhouse Wellness, a cannabis-based dispensary located in Maine, USA.
Alongside Gina Dubbé, Leslie co-authored a book titled “High Heals: How Two Women Found Their Footing in the Medical Cannabis Industry,” offering insights into the cannabis industry’s inner workings. Furthermore, they launched a line of cannabis products specifically designed for women called Blissiva.
Currently, Leslie holds the position of Editor-in-Chief at the American Journal of Endocannabinoid Medicine , This journal holds the distinction of being the first and only scientific publication in North America that focuses on evidence-based endocannabinoid medicine.
Ana Hounie
Ana Hounie
Ana Hounie graduated in Medicine from the Federal University of Pernambuco (1994) and has a PhD in Sciences, in the area of Psychiatry from the University of São Paulo-FMUSP (2003).
She completed her postdoctoral studies at the School of Medicine of USP. She works mainly in the treatment and research of Obsessive-Compulsive Disorder and Tourette Syndrome, having published a book on the latter syndrome, in which she is one of the leading experts in Brazil.
Currently, she is dedicated to the study of medicinal cannabis, in which she has had clinical experience since 2016, conducting courses and lectures on the subject.
Natasha Consul
Natasha Consul
Full Member and Title of Specialist by the Brazilian Academy of Neurology Specialization in Movement Disorders by Unifesp-EPM Specialization in Application of Therapeutic Botulinum Toxin Unifesp-EPM and HC-USP.
Certified by the Brazilian Academy of Integrative Functional Medicine Preceptor of the Medical Course at PUC-SP Prescriber of cannabinoid derivatives since 2018, with more than 600 patients under follow-up.
Lecturer and mentor in the prescription of phytocannabinoids, with more than 100 classes taught in the last 03 years.
Victor Marçal Saab
Victor Marçal Saab
Dr Victor Marçal Saab graduated from the University of Marília and completed a medical residency in neurology at the Santa Casa de Misericórdia in São Paulo. He holds a specialist title in neurology from the ABN and AMB, he completed a post-graduate course in Epilepsy from HSPE and in Demyelinating Diseases from CATEM.
Dr Victor is dedicated to the study of the Endocannabinoid System and the use of Medicinal Cannabis. Today, he attends to a significant number of patients in his clinic using this therapeutic tool.
Vinicius Barbosa
Vinicius Barbosa
Psychiatrist graduated in Medicine from the Pontifical Catholic University of São Paulo. Medical Residency in Psychiatry at the Dr. Cândido Ferreira Health Service in Campinas.
Cândido Ferreira in Campinas and Fellow in Child and Adolescent Psychiatry with emphasis on Autism and Early Schizophrenia at the Hospital de Ville Evrard in Paris, France.
He is a guest lecturer on the Extension course at the Faculty of Pharmaceutical Sciences at Unicamp. Vinícius Barbosa is currently coordinator of the Medicinal Cannabis Center at the Sírio Libanês Hospital in São Paulo and conducts research into the use of cannabinoids in autism.
Bárbara Barreiros
Bárbara Barreiros
Family and Community Doctor graduated from GHC-RS, Master’s Degree in Evaluation and Production of SUS Health Technologies from Escola GHC – Grupo Hospitalar Conceição, Specialist in Medical Residency Preceptorship from Hospital Sírio-Libanês, International Certification in Endocannabinoid Medicine from Wecann Academy. She has been working in the SUS since 2007 in the areas of management, assistance and teaching, and coordinates the Family and Community Medicine Residency in São Bernardo do Campo. In 2020, she started the IAPS (Institute of Primary Health Care) project with a focus on comprehensive person-centered care, introducing medicinal cannabis as a therapeutic tool in 2021.
Alessandra Lindmayer
Alessandra Lindmayer
Dermatologist from Santa Casa de Sao Paulo, full member of the Brazilian Society of Dermatology. Postgraduate in cutaneous oncology at HC-FMUSP. Certified in Endocannabinoid Medicine by WeCann Academy.
SCIENTIFIC PROGRAMMING
NOV 24th
FRIDAY
NOV 25th
SATURDAY
WeCann Summit Opening
WeCann Summit Opening.
Patricia Montagner (BRA)
IACM’s Introduction.
Franjo Grotenhermen (DEU) | *online participation
Lecture
The endocannabinoid system and its central relevance in maintaining homeostasis.
Adán de Salas Quiroga (ESP)
Lecture
Medical cannabis: searching for the evidence.
Uwe Blesching (US)
Round Table
Presentation of the Medical Cannabis Evidence Map.
Patricia Montagner (BRA)
Institutional perspectives
Brazilian Institutional
representatives to be confirmed
Lecture
Therapeutic potential of cannabis in psychiatric disorders.
Kirsten Müller-Vahl (DEU)
Round Table
Role of the endocannabinoid system in pain control.
Ricardo Ferreira (BRA)
Therapeutic potential of cannabis in chronic pain.
Tina Hoersted (DNK)
Keynote lecture
The endocannabinoid system: the cornerstone between stress regulation and energy metabolism.
Daniele Piomelli (US)
Round Table
Role of the endocannabinoid system in brain development and neurological disorders.
Javier Diaz Alonso (ESP)
Therapeutic potential of cannabis in autism
and other neurodevelopmental disorders.
Adi Aran (IL)
Round Table
Role of the endocannabinoid system in the control of brain excitability.
Mery Peña (COL)
Therapeutic potential of cannabis in epilepsy.
Eduardo Faveret (BRA)
Lecture
Therapeutic potential of cannabis
in neurodegenerative diseases.
Natasha Consul (BRA)
WeCann Talks
Therapeutic potential of cannabis in gynecological disorders.
Leslie Apgar (US)
WeCann Talks
Beyond THC and CBD: therapeutic potential of minor constituents in cannabis.
Mariano Garcia (ESP)
WeCann Talks
Cannabis Hyperemesis Syndrome (CHS).
Ethan Russo (US) | *online participation
WeCann Talks
Therapeutic potential of cannabis in cancer and palliative care.
Paola Pineda (COL)
WeCann Talks
Psychoactivity vs. psychotoxicity: how to avoid undesired effects?
Alberto Ulloa (COL)
WeCann Talks
Medical cannabis efficacy: what lies behind the differences in the results from clinical trials and real-world evidence?
Guillermo Moreno-Sanz (ESP)
WeCann Talks
Placebo and nocebo effects of medical cannabis: how to avoid them?
Ricardo Ferreira (BRA)
Keynote lecture
Adverse effects, drug-drug interactions,
and practical clinical pearls.
Franjo Grotenhermen (DEU) | *online participation
Round Table
Pharmacokinetics and routes of administration.
Adán de Salas Quiroga (ESP)
Cannabis as Medicine: pharmaceutical grade products.
Mara Gordon (US)
Raphael Mechoulam Plenarium tribute
Full spectrum products vs. isolated products.
José Alexandre Crippa (BRA)
Ethan Russo (US)
| *online participation
The entourage effect debate.
Guillermo Moreno-Sanz (ESP)
Franjo Grotenhermen (DEU)
| *online participation
WeCann Rounds
Clinical case discussions – Chronic pain
(joint pain, neuropathic pain, fibromyalgia, migraine).
Ricardo Ferreira (BRA)
Tina Horsted (DNK)
Harry MacIlroy (US)
WeCann Rounds
Clinical case discussions – Psychiatry
(anxiety disorders, psychotic disorders, Tourette’s, chemical dependence).
Kirsten Müller-Vahl (DEU)
Wilson Lessa (BRA)
Alberto Ulloa (COL)
WeCann Rounds
Clinical cases discussion – Neuropediatrics
(Epilepsy, Cerebral Palsy, ASD, ADHD).
Eduardo Faveret (BRA)
Diego Cruz (CHL)
Vinicius Barbosa (BRA)
WeCann Rounds
Clinical case discussions – Neurodegenerative diseases (Alzheimer Disease, Parkinson Disease, Multiple Sclerosis, Progressive Supranuclear Palsy).
Mery Peña (COL)
Victor Saab (BRA)
Ana Hounie (BRA)
WeCann Rounds
Clinical cases discussions – Oncology
(Cancer, palliative care).
Leandro Ramires (BRA)
Mariano Garcia (ESP)
Diego Cruz (CHL)
WeCann Rounds
Clinical case discussions – Miscellaneous
(skin diseases, gynecological disorders, gastrointestinal disorders).
Leslie Apgar (US)
Harry MacIlroy (US)
Alessandra Lindmayer (BRA)
WeCann Summit Closure
The most remarkable cases in my career & final messages.
Leandro Ramires (BRA)
Paola Pineda (COL)
Vinicius Barbosa (BRA)
Mariano Garcia (ESP)
Guarantee your Passport
STANDARD
BRL 1,697.00
WeCann Students (%OFF)
EXPERIENCE +
BRL 3,497.00
WeCann Students (%OFF)
Technical Cooperation
With its strong legacy of commitment to the scientific understanding of cannabinoid derivatives and their therapeutic applications, the IACM supports a congress in Latin America for the first time, and is teaming up with WeCann Academy to share highly qualified and reliable scientific knowledge on the subject.
Institutional Support
Official Sponsors
MASTER
PREMIUM
BUSINESS
Royal Palm Hall
The Centro de Convesções Royal Palm Hall – The Royal Palm Hall Convention Center-, the anchor of the Royal Campinas complex, offers the most complete infrastructure for events in Brazil.
Conceived under the concept of total flexibility, it was selected for its high technology and privileged logistics to exceed all expectations and make your experience at the WeCann Summit 2023 even more memorable!
PLACE OF THE EVENT
R. Mns Luís Fernandes de Abreu, 311 - Jardim do Lago Continuacao, Campinas - SP, 13051-093
Produced by
WeCann Academy
WeCann Academy is a global community that brings together leading national and international experts in the field in a tailor-made ecosystem designed to provide an immersive and differentiated learning experience exclusively for doctors.
Its Community includes physician colleagues from 15 countries and is growing all the time.
WeCann is also the creator and organizer of Jornada A Nova Fronteira da Medicina, the largest online event on Endocannabinoid Medicine in Latin America, which has been attended by more than 30,000 physicians from 59 countries.
Would you like to save on accommodation + airfare + transfer to attend WeCann Summit 23?
Check out the best packages that APINO, the event’s official partner agency, has selected for you to travel in comfort and tranquility (and with the best conditions available on the market!)
Frequently Asked Questions
The event will take place at Royal Palm Hall in Campinas – SP, on November 24 and 25, 2023.
Included in the passport price (Standard and Experience+) is a light lunch with finger food on both days of the event.
The Experience+ passport also includes dinner with the WeCann Academy Experts on Thursday (November 23rd).
The WeCann Summit program will include more than 30 hours of content with more than 45 speakers who have extensive practical and academic experience with Endocannabinoid Medicine. Throughout the 2-day event, we will have 2 parallel content tracks, divided between lectures and round tables, bringing the most current and relevant topics on the subject, in Brazil and around the world.
Follow the event’s official communication channels and our Instagram page @wecann.summit to receive more information in real time.
To request information on the organizing company, please send an e-mail to [email protected].
We offer special conditions for packages of 20 passports or more. Please send an e-mail to [email protected] with the subject “Package information” for more information.
Within 7 days of your purchase, you can request a full refund of the passport. After this period, you can only change the ownership of the passport, or request the conversion of the amount paid into credit to be used on any WeCann Academy product. To request cancellation, send an e-mail to [email protected] with the subject “Passport cancellation”. Please be aware of the cancellation policies in our Ticket Purchase Agreement.
Send an e-mail to [email protected] with the details of the original purchaser and the details of the new holder, requesting a change of ownership. Please be aware of the exchange policies in our Ticket Purchase Agreement.
The Experience dinner will take place on Thursday, November 23rd. We therefore recommend that participants in the Experience+ category plan their arrival for Thursday, so that they can attend the dinner.
Yes, there is parking lot at the Royal Palm Hall Campinas. The amount charged for parking is not included in the Passport (it will be the responsibility of the participant).
The Royal Palm Campinas events complex has 12 gastronomic options, integrated with 3 hotels offering economy, upper midscale and luxury accommodation.
Our partner agency, Apino Turismo, will provide discounts and vouchers on flights and hotels for WeCann Summit 2023 participants. Click on the following link to be directed to the agency’s service desk Apino Turismo
Please contact our commercial team via the form available on this page Open the form and wait for us to get back to you. Or, if you prefer, contact us directly by WhatsApp by clicking here.
Click here and fill in the press pre-registration form for the WeCann Summit 2023.
Simultaneous translation into Portuguese, English and Spanish is included in the price of the passport (Standard e Experience+).
